Aimmune Therapeutics Completes IPO
August 5, 2015 – Aimmune Therapeutics announced today the pricing of its initial public offering at $16.00 per share. Trading is to begin tomorrow on NASDAQ under the symbol AIMT. Company press release. FLG partner: Victor Colunga.
Read MorePan Pacific Bank Names FLG Partner Eric Hall to its Board of Directors
July 22, 2015 – Today Pan Pacific Bank Names FLG Partner Eric Hall to its Board of Directors. Press release.
Read MoreLiquid Light Signs Agreement with Coca-Cola Company
July 20, 2015 – FLG client Liquid Light announced it has signed a technology development agreement with the Coca-Cola Company. Company press release. FLG partner: Chris Lowe.
Read MoreOculeve is Acquired by Allergan
July 6, 2015 – Today FLG client Oculeve, a development stage company focused on treatments of dry eye diseases, accounted that it has agreed to be acquired by Allergen plc. Oculeve press release. FLG partner: Mark Murray.
Read MoreAllergen Research Changes Its Name to Aimmune Therapeutics
FLG client Allergen Research Corporation has changed its name to Aimmune Therapeutics. Company press release.
Read More